C-19 Vaccines Update: New advice for the Oxford/AZ vaccine

C-19 Vaccines Update: New advice for the Oxford/AZ vaccine

April 8, 2021

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued new advice to COVID-19 vaccination providers about the use of the Oxford/AstraZeneca vaccine.

Updated information is being provided for healthcare professionals on the possible risk of extremely rare and unlikely to occur specific types of blood clots following vaccination with the COVID-19 Oxford/AstraZeneca vaccine.

Following a thorough review into reports of a very rare type of blood clot in the brain, the MHRA is advising that everybody who has already had a first dose of the AstraZeneca vaccine should receive a second dose of the same brand, irrespective of age, except for the very small number of people who experienced blood clots with low platelet counts from their first vaccination. It also recommends that, as a precaution, it is preferable for people under the age of 30 with no underlying health conditions to be offered an alternative vaccine where possible once they are eligible.

In a statement, the Department of Health and Social Care (DHSC) and the Joint Committee on Vaccination and Immunisation (JCVI) have issued supporting statements indicating that they will follow the MHRA’s updated advice. Public Health England (PHE) and NHS England and NHS Improvement (NHSE&I) have also provided update for those being offered COVID-19 vaccines, and for health professionals.

MHRA press release

PHE guidance: COVID-19 vaccination and blood clotting

NHSE&I letter: Announcement regarding AstraZeneca vaccine and next steps


Posted in: ,

More Latest News >